Fate Therapeutics Inc entered into an underwriting agreement to issue and sell 14,545,454 shares of common stock at an offering price of $5.50 per share, with estimated net proceeds of approximately $74.7 million, and also entered into a securities purchase agreement with Redmile Group to purchase pre-funded warrants for approximately $20.0 million.